Abzena vs WuXi Biologics: CDMO Comparison

Side-by-side comparison of Abzena and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Abzena → 64.0
San Diego, CA; Bristol, PA; Cambridge, UK
Signal Score
64/100
Quality (FDA + GMP)
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Available
Modalities
ADC, AOC, RDC, PDC, DAC, Fusion Proteins, Bispecifics, bsAbs, Multispecifics, msAbs, Bioconjugates, Biologics, mAb, Monoclonal Antibody, Antibodies, Cytokines, HPAPI, Bioconjugation
Shanghai, CN · Wuxi, CN
Signal Score
84/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Modalities
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody

Key differences

  • WuXi Biologics holds 3 active EMA GMP certificates; Abzena does not appear in EudraGMDP.
  • WuXi Biologics maintains 1 MHRA / UK GMP certificate; Abzena does not.
  • Composite Signal Score: WuXi Biologics 84/100 vs Abzena 64/100 — a 20-point gap reflecting the combined quality, capacity and financial signal.

On a 13-modality CDMO landscape, both Abzena and WuXi Biologics qualify as ADC manufacturers; WuXi Biologics carries the higher composite Signal Score for ADC programs in this comparison.

What to evaluate for ADC programs

Both Abzena and WuXi Biologics qualify as ADC CDMOs. When choosing between them for ADC programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

HPAPI containment

Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.

Linker-payload chemistry on file

Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.

Commercial bioconjugation track record

Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.

Integrated DS + DP

Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.

See all ADC CDMOs ranked by Signal Score →

Frequently asked: Abzena vs WuXi Biologics

How do Abzena and WuXi Biologics compare on European GMP coverage?

Abzena holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for ADC manufacturing — Abzena or WuXi Biologics?

Both Abzena and WuXi Biologics are tagged as ADC CDMOs in our directory, so both are credible options for ADC programs. The most important differentiator for ADC selection is typically hpapi containment: Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Abzena carries a Signal Score of 64/100 and WuXi Biologics carries 84/100 — a meaningful lead for WuXi Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Abzena and WuXi Biologics for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.